undamentalytics Newsletter
Sign in

Vivos Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Vivos Therapeutics, Inc. had an operating margin of -114.1% and a current ratio of 0.24. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Gross margin76.0%79.7%74.6%62.5%59.9%60.0%60.4%61.9%
Operating margin−92.8%−92.1%−120.7%−156.2%−125.3%−74.3%−114.1%−107.9%
Net margin−94.4%−92.3%−120.2%−148.8%−98.4%−74.1%−121.4%−121.8%
Free-cash-flow margin−48.4%−44.4%−107.4%−128.0%−92.4%−88.2%−100.9%−91.0%
Return on equity—−172.6%−95.6%−157.2%————
Return on assets−142.4%−73.3%−68.8%−100.6%−111.1%−85.6%−104.7%−103.3%
Asset turnover1.510.790.570.681.131.160.860.85
Current ratio0.222.603.640.800.341.500.240.21
Debt to equity—7.6%5.0%—292.0%15.1%——
Interest cover (operating income ÷ interest)n/mn/mn/m———n/mn/m
R&D as % of revenue——1.2%1.2%0.7%0.7%0.6%—
Capital spending as % of revenue1.5%0.9%14.2%5.8%5.8%3.8%13.4%9.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

0 of 5 checks passed · June 30, 2026
What it owns · $24m
Short-term assets $4mLonger-term assets $20m
What it owes, and who funded it · $28m
Short-term liabilities $20mLonger-term liabilities $8mShareholders' equity $-4m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $20m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $8m of longer-dated liabilities.
  • More cash than debt $2m of cash against $8m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$17m of operating cash flow against $8m of debt.
  • Operating profit covers interest at least five times over Operating income of −$23m against $4m of interest.

From Vivos Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

30 /100

Weak moat

How hard Vivos Therapeutics's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -75.7% of total assets over 5 years.

  • Pricing power 14 / 20

    Gross margin has been a median 61.1%, moving by 7.8 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -107.4%; its worst year was -158.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -98.4% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: NEPH vs VVOSVVOS vs ZJYLSNOA vs VVOSBDMD vs VVOS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Vivos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vivos Therapeutics, Inc.